Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on June 5, 2025
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 5, 2025
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, …
Annovis to Host Webinar and Live Q&A on June 24, 2025
GlobeNewswire
·
June 5, 2025
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s …
DiagnaMed Expands Clean Hydrogen Energy Extraction Capabilities to Demonstrate Proof of Concept of Proprietary Technology
GlobeNewswire
·
June 5, 2025
TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a Canadian technology innovator specializing in advanced hydrogen extraction technologies, is pleased to announce its recent …
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
GlobeNewswire
·
June 5, 2025
Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat …
Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
GlobeNewswire
·
June 5, 2025
BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) …
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
GlobeNewswire
·
June 5, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
Kestra Medical Technologies Announces Appointment of Conor Hanley to its Board of Directors
GlobeNewswire
·
June 5, 2025
KIRKLAND, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Conor Hanley as an independent director to its board, …
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
GlobeNewswire
·
June 5, 2025
LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of …
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
GlobeNewswire
·
June 5, 2025
EMA Orphan Drug Designation (ODD) builds on U.S. Food …
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt Disease
GlobeNewswire
·
June 5, 2025
VeonGen advances two proprietary, first-in-class gene therapies in the clinic, enabled by its novel vgRNA REVeRT and vgAAV technology platforms Lead program VG801 receives FDA Rare Pediatric Disease Designation and is progressing in a first-in-human Phase …
Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty
GlobeNewswire
·
June 5, 2025
AMSTERDAM, June 05, 2025 (GLOBE NEWSWIRE) -- Polpharma Group, a leading European pharmaceutical manufacturer, has joined fellow members of Medicines for Europe in signing an open letter addressed to the Prime Ministers and Ministers of Health of all 27 EU …
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
GlobeNewswire
·
June 5, 2025
CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: …
Kailera Therapeutics Appoints Adam Koppel and Christopher Hite to Board of Directors
GlobeNewswire
·
June 5, 2025
BOSTON and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today …
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
GlobeNewswire
·
June 5, 2025
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra …
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
GlobeNewswire
·
June 5, 2025
- DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model - WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people …
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
GlobeNewswire
·
June 5, 2025
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, …
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
GlobeNewswire
·
June 5, 2025
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S …
The Joint Corp. Announces $5 Million Stock Repurchase Program
GlobeNewswire
·
June 5, 2025
SCOTTSDALE, Ariz., June 05, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, announced that its board of directors has authorized a stock repurchase program …
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
GlobeNewswire
·
June 5, 2025
Upfront fees and near-term development milestone payments totaling up to $11 million Sales milestones of $150 million or more in first 10 years of commercialization Royalties equaling 25% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., …
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
GlobeNewswire
·
June 5, 2025
Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) …